[1] YIN S, MA Z.Electrochemical immunoassay for tumor markers based on hydrogels[J].Expert Rev Mol Diagn, 2018, 18(5):457-465.
[2] FOERSTER F, GALLE P R.Comparison of the current international guidelines on the management of HCC[J].JHEP Rep, 2019, 1(2):114-119.
[3] FARIA S C, SAGEBIEL T, PATNANA M, et al.Tumor markers:myths and facts unfolded[J].Abdom Radiol(NY), 2019, 44(4):1575-1600.
[4] DUFFY M J.Tumor markers in clinical practice:a review focusing on common solid cancers[J].Med Princ Pract, 2013, 22(1):4-11.
[5] OREMEK G M, SAUER-EPPEL H, BRUZDZIAK T H.Value of tumour and inflammatory markers in lung cancer[J].Anticancer Res, 2007, 27(4A):1911-1915.
[6] CHO W C.Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer[J].Biomed Pharmacother, 2007, 61(9):515-519.
[7] WANG B, HE Y J, TIAN Y X, et al.Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer[J].Asian Pac J Cancer Prev, 2014, 15(22):9611-9614.
[8] YANG A P, LIU J, LEI H Y, et al.CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer[J].Clin Chim Acta, 2014, 437:183-186.
[9] RAO H, WU H M, HUANG Q Y, et al.Clinical value of serum CEA, CA24-2 and CA19-9 in patients with colorectal cancer[J].Clin Lab, 2021, 67(4):200828.
[10] ETZIONI R, URBAN N, RAMSEY S, et al.The case for early detection[J].Nat Rev Cancer, 2003, 3(4):243-252.
[11] STOSS O, HENKEL T.Biomedical marker molecules for cancer-current status and perspectives[J].Drug Discovery Today, 2004, 3(6):228-238.
[12] MEEK D W.Regulation of the p53 response and its relationship to cancer[J].Biochem J, 2015, 469(3):325-346.
[13] BHUTIA Y D, OGURA J, GRIPPO P J, et al.Chronic exposure to excess iron promotes EMT and cancer via p53 loss in pancreatic cancer[J].Asian J Pharm Sci, 2020, 15(2):237-251.
[14] SAAVEDRA K, VALBUENA J, OLIVARES W, et al.Loss of expression of reprimo, a p53-induced cell cycle arrest gene, correlates with invasive stage of tumor progression and p73 expression in gastric cancer[J].PLoS One, 2015, 10(5):e0125834.
[15] ABAT D, DEMIRHAN O, INANDIKIOGLU N, et al.Genetic alterations of chromosomes, p53 and p16 genes in low-and high-grade bladder cancer[J].Oncol Lett, 2014, 8(1):25-32.
[16] OCHS-BALCOM H M, MARIAN C, NIE J, et al.Adiposity is associated with p53 gene mutations in breast cancer[J].Breast Cancer Res Treat, 2015, 153(3):635-645.
[17] YAO W, QIN X, QI B, et al.Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma[J].Int J Clin Exp Pathol, 2014, 7(10):7158-7163.
[18] READ M L, SEED R I, MODASIA B, et al.The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer[J].Mol Carcinog, 2014, 55(1):15-26.
[19] 王慧香, 徐孟宇, 余晖, 等.p16、Ki-67和P53在高级别宫颈鳞状上皮内病变精准诊断中的价值[J].中国实验诊断学, 2021, 25(7):977-980.
[20] NITTNER D, LAMBERTA I, CLERMONT F, et al.Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation[J].Nat Cell Biol, 2012, 14(9):958-965.
[21] BERMAN S D, CALO E, LANDMAN A S, et al.Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage[J].Proc Natl Acad Sci U S A, 2008, 105(33):11851-11856.
[22] ZHU S, MOTT R T, FRY E A, et al.Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer[J].Am J Pathol, 2013, 183(4):1339-1350.
[23] VENZA M, VISALLI M, BIONDO C, et al.Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma[J].Biochim Biophys Acta, 2015, 1849(3):247-256.
[24] HARBOUR J W, DEAN D C.The Rb/E2F pathway:expanding roles and emerging paradigms[J].Genes Dev, 2000, 14(19):2393-2409.
[25] MEDEN H, FATTAHI-MEIBODI A, MARX D.ELISA-based quantification of p105(c-erbb-2, her2/neu) in serum of ovarian carcinoma[J].Methods Mol Med, 2001, 39:125-133.
[26] CHEUNG T H, WONG Y F, CHUNG T K, et al.Clinical use of serum c-erbB-2 in patients with ovarian masses[J].Gynecol Obstet Invest, 1999, 48(2):133-137.
[27] HELLSTROM I, GOODMAN G, PULLMAN J, et al.Overexpression of HER-2 in ovarian carcinomas[J].Cancer Res, 2001, 61(6):2420-2423.
[28] 黄美园, 杨珍玉, 邓爽, 等.宫颈癌患者血清miR-574-5p和miR-497-5p表达的临床意义[J].现代医学, 2021, 49(4):377-384.
[29] TOIYAMA Y, TAKAHASHI M, HUR K, et al.Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer[J].J Natl Cancer Inst, 2013, 105(12):849-859.
[30] ZHAO S, YANG G, MU Y, et al.MiR-106a is an independent prognostic marker in patients with glioblastoma[J].Neuro Oncol, 2013, 15(6):707-717.
[31] MORIN R D, O'CONNOR M D, GRIFFITH M, et al.Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells[J].Genome Res, 2008, 18(4):610-621.
[32] YELAMANCHILI S V, MORSEY B, HARRISON E B, et al.The evolutionary young miR-1290 favors mitotic exit and differentiation of human neural progenitors through altering the cell cycle proteins[J].Cell Death Dis, 2014, 5(1):e982.
[33] LI A, YU J, KIM H, et al.MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls[J].Clin Cancer Res, 2013, 19(13):3600-3610.
[34] YANG G, LU X, YUAN L.LncRNA:a link between RNA and cancer[J].Biochim Biophys Acta, 2014, 1839(11):1097-1109.
[35] SPIZZO R, ALMEIDA M I, COLOMBATTI A, et al.Long non-coding RNAs and cancer:a new frontier of translational research?[J].Oncogene, 2012, 31(43):4577-4587.
[36] LV X B, LIAN G Y, WANG H R, et al.Long noncoding RNA HOTAIR is a prognostic marker for esophageal squamous cell carcinoma progression and survival[J].PLoS One, 2013, 8(5):p.e63516.
[37] CHEN T, XIE W, XIE L, et al.Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer[J].Biochem Biophys Res Commun, 2015, 468(4):666-670.
[38] AUGOFF K, MCCUE B, PLOW E F, et al.miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer[J].Mol Cancer, 2012, 11:5.
[39] 杜涛, 张顺, 崔锡茂, 等.长链非编码RNA WT1-AS预测胃癌新辅助化疗疗效的临床价值[J].同济大学学报(医学版), 2021, 42(5):612-615.
[40] PAN Q, HAN T T, LI G P.Novel insights into the roles of tRNA-derived small RNAs[J].RNA Biol, 2021, 18(12):2157-2167.
[41] LI S, XU Z, SHENG J.tRNA-derived small RNA:a novel regulatory small non-coding RNA[J].Genes 2018, 9(5):246.
[42] ELKORDY A, MISHIMA E, NIIZUMA K, et al.Stress-induced tRNA cleavage and tiRNA generation in rat neuronal PC12 cells[J].J Neurochem, 2018, 146(5):560-569.
[43] MO D P, HE F, ZhENG J Y, et al.tRNA-derived fragment tRF-17-79MP9PP attenuates cell invasion and migration via THBS1/TGF-β1/Smad3 axis in breast cancer[J].Front Oncol, 2021, 11:656078.
[44] GOODARZI H, NGUYEN H C B, ZHANG S, et al.Modulated expression of specific tRNAs drives gene expression and cancer progression[J].Cell, 2016, 165(6):1416-1427.
[45] SHIMIZU M, TANAKA N.IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells[J].Oncogene, 2019, 38(9):1520-1533.
[46] SHAN Y, HE X, SONG W, et al.Role of IL-6 in the invasiveness and prognosis of glioma[J].Int J Clin Exp Med, 2015, 8(6):9114-9120.
[47] 巩艳青, 辛钟成, 郭应禄.肿瘤干细胞表面标记物的研究进展[J].中华临床医师杂志, 2010, 4(11):2197-2200.
[48] ELBASATEENY S S, SALEM A A, ABDELSALAM W A, et al.Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer[J].Pathol Res Pract, 2016, 212(1):10-16.
[49] TRINIDAD C V, TETLOW A L, BANTIS L E, et al.Reducing ovarian cancer mortality through early detection:approaches using circulating biomarkers[J].Cancer Prev Res(Phila), 2020, 13(3):241-252.
[50] XU R H, WEI W, KRAWCZYK M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J].Nat Mater, 2017, 16(11):1155-1161.
[51] CHEN X, GOLE J, GORE A, et al.Non-invasive early detection of cancer four years before conventional diagnosis using a blood test[J].Nat Commun, 2020, 11(1):3475.
[52] LIU M C, OXNARD G R, KLEIN E A, et al.Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA[J].Ann Oncol, 2020, 31(6):745-759.
[53] 程其军, 刘意, 许剑利.外周血ctDNA中PCDH8和PCDH17基因甲基化在高级别浆液性卵巢癌筛查和预后中的临床价值[J].东南大学学报(医学版), 2022, 41(3):394-401. |
